obesity, diabetes and bariatric surgerymediquest.in/did2016data/day 2/4 obesity, diabetes and...
TRANSCRIPT
©2012 MFMER | slide-1
Obesity, Diabetes and Bariatric Surgery
Adrian Vella MD FRCP (Edin.), Mayo Clinic, Rochester, MN
Learning Objectives
• Understand gastrointestinal physiology, gut hormones and glucose metabolism
• Understand the effect of caloric restriction on glucose metabolism
• Understand the physiological differences between different bariatric procedures and the role of GLP-1 in glucose metabolism
• Understand the risks and benefits of bariatric interventions
©2012 MFMER | slide-2
Effect of Bariatric Surgery on Diabetes
• A meta-analysis of 136 studies of bariatric surgery which included a total of 22,094 patients
• 1417 of 1846 (76%) patients experienced complete resolution
• Diabetes resolved in 98.9% of patients undergoing DS
• 83.7% for RYGB and 47.9% for AGB
Buchwald et al. JAMA 292, 2004
Why does bariatric surgery benefit carbohydrate metabolism?
• Foregut hypothesis: - the foregut elaborates a diabetogenic factor
• Isolation of the foregut and separation from nutritional input decreases secretion of this factor
• Hindgut hypothesis: - the hindgut secretes a factor that improves handling of a nutritional load
• Increased delivery to the distal intestine increases secretion of this factor
The gut as an endocrine organ • The gut is not a monolithic
organ and comprises multiple cell types (neural, muscle, exocrine, endocrine)
• It is responsible for the integration of multiple peripheral and central signals necessary for the maintenance of body weight
Gut Hormones
Chaudhri et al. Annual Review of Physiology, 2008.
Ghrelin
Amylin
Background: Regulation of Gastric Emptying
+ve -ve
Myenteric plexus
-ve
Mechanoceptors
Myenteric plexusMyenteric plexusChemoreceptors
CCK Gastrin GIP GLP-1 PYY
-ve
Food ingestion Vagus
Delgado-Aros S, et al. AJP Gastrointest Liver Physiol. 2002;282(3):G424-431.
99mTc-SPECT Technique to Measure Gastric Volume
Measurement of Gastric Accommodation
GLP-1 (7,36) GLP-1 (9,36) ACTIVE HORMONE INACTIVE HORMONE
GLP-1 Receptor
Exendin-4 (7,39) Exendin-4 (9,39)
Agonist Antagonist
Differences in function during antagonist administration can be attributed to the actions of GLP-1
Mechanisms
Malabsorption – due to bypass of proximal intestine
Creation of a gastric pouch with decreased volume and compliance
Partial or complete vagotomy
Caloric Restriction • Kelley DE et al: Relative effects of calorie
restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 77:1287-1293, 1993
• Wadden TA et al: A multicenter evaluation of a proprietary weight reduction program for the treatment of marked obesity. Arch Intern Med 152:961-966, 1992
Glu
cose
upt
ake
(mg/
min
/m2 )
Weight (kg) 92.7 90.5 77.9 76.2
J Clin Endocrinol Metab 77:1287, 1993
300
200
100
P <0.001
ns
P <0.01
Pre weight loss Post weight loss
Caloric balance Caloric restriction (800 kcal/d x 7d)
Independent Effects of Acute Calorie Restriction and Weight Loss on Insulin Sensitivity in Type 2 DM
Sathananthan. J Nutr 2015;145:2046-51.
Sathananthan. J Nutr 2015;145:2046-51.
Sathananthan. J Nutr 2015;145:2046-51.
Sathananthan. J Nutr 2015;145:2046-51.
Can Bariatric Surgery Provide Mechanistic Insights into Gut-Pancreas Interactions?
©2012 MFMER | slide-17
Vella A, Diabetes (2013) 62(9): 3017-3018
4
“Remission” = < 126mg/dL, HbA1c < 6.2%
Dixon JB; JAMA. 299(3):316-23, 2008 Jan 23.
Sleeve Gastrectomy & Duodenal Switch
Abu Dayyeh B et al. Rev Esp Enferm Dig (Madrid Vol. 106, N.º 7, pp. 467-476, 2014
Nguyen NT et al. Journal of the American College of Surgeons 2013 :216(2);252 - 257
©2012 MFMER | slide-22
Procedure Pro Cons AGB Simple to place
Can be adjusted No malabsorption Can be effective
Prone to migration Device failure Not effective in the long term
RYGB Established Known efficacy
Malabsorptive Risk of „dumping‟ and post-RYGB hypoglycemia Cost and long-term f/u
SG Simple procedure No malabsorption Less f/u necessary
? Long-term efficacy Not really cheaper or assn. with less complications than RYGB
DS / long-limb RYGB / Scopinaro
Effective for high BMI High morbidity Needs v close f/u Poorer QOL
Karamanakos S. et al. Annals of Surgery. 247(3):401-407, March 2008.
VAS recorded appetite changes after LRYGBP (--[black up pointing small triangle]--) and LSG (--[black small square]--).
Weight Loss, Appetite Suppression, and Changes in Fasting and Postprandial Ghrelin and Peptide-YY Levels After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy: A Prospective, Double Blind Study.
RYGB
SG
STAMPEDE
©2012 MFMER | slide-24
Shauer PR, NEJM 2012; 366:1567-1576
2 years after STAMPEDE
©2012 MFMER | slide-25
RYGB SG IMT n 18 19 17
Female (%) 44 84 47
HbA1c (%) 6.7 ± 1.2 7.1 ± 0.8 8.4 ± 2.3
% Body Fat -16 -10
Insulin Action 2.7 x
DI 5.8 x
Kashyap SR, Diabetes Care 2013; 36:2175-2182
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 3-Year Outcomes
©2012 MFMER | slide-26
Schauer PR, NEJM (2014) Mar 31
Mechanisms
Malabsorption – due to bypass of proximal intestine
Creation of a gastric pouch with decreased volume and compliance
Partial or complete vagotomy
[6,6-2H2] Glucose Infusion
-180 360
Meal at 0 mins labeled with [1-13C] Glucose and 111In
0
[6-3H] Glucose infusion
-30 300
Gamma Camera
111In in egg meal
+ / - Exendin-9,39 @ 300pmol/kg/min
Post-RYGB Controls
©2012 MFMER | slide-29
Shah M, Diabetes (2014) 63(2): 483-493
Post-RYGB Controls
©2012 MFMER | slide-30
Shah M, Diabetes (2014) 63(2): 483-493
Post-RYGB Controls
©2012 MFMER | slide-31
Shah M, Diabetes (2014) 63(2): 483-493
Post-RYGB Controls
©2012 MFMER | slide-32
* *
Shah M, Diabetes (2014) 63(2): 483-493
Post-RYGB Controls
©2012 MFMER | slide-33
*
Shah M, Diabetes (2014) 63(2): 483-493
Post-RYGB Controls
©2012 MFMER | slide-34
Shah M, Diabetes (2014) 63(2): 483-493
• Jimenez A et al: GLP-1 Action and Glucose Tolerance in Subjects With Remission of Type 2 Diabetes After Gastric Bypass Surgery. Diabetes Care 2013;36:2062-2069
• 750pmol/kg/min – 18% change in glucose
• Jorgensen NB et al: The exaggerated glucagon-like peptide-1 response is important for the improved beta-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 2013;62(9):3044-52
• 900pmol/kg/min – 25% change in glucose
©2012 MFMER | slide-35
Diabetes Surgery Study
©2012 MFMER | slide-36
Ikramuddin S, JAMA 2013; 309(21) :2240-2249
Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery
©2012 MFMER | slide-37
Still et al. Lancet Diabetes Endocrinol. 2014 Jan; 2(1): 38–45
Beta-Cell mass does not change after RYGB
©2012 MFMER | slide-38
Dirksen C et al. Diabetologia. 2013 Dec;56(12):2679-87.
Mechanisms
Malabsorption – due to bypass of proximal intestine
Creation of a gastric pouch with decreased volume and compliance
Partial or complete vagotomy
Blockade of the Vagal Nerve by Overdrive Electrical Stimulation
Camilleri M et al. Surgery 2008:143:6 :723 -731
Blockade of the Vagal Nerve by Overdrive Electrical Stimulation
0
500
1000
1500
2000
2500
Pre-Implant (n=10) Week 4 (n=10) Week 12 (n=8) Week 26 (n=9)
kcal
Fat Carbohydrates Protein
Camilleri M et al. Surgery 2008:143:6 :723 -731
Sathananthan, M., et al. (2014). Diabetes, metabolic syndrome and
obesity : targets and therapy 7: 305-312.
Sathananthan, M., et al. (2014). Diabetes, metabolic syndrome and
obesity : targets and therapy 7: 305-312.
Sathananthan, M., et al. (2014). Diabetes, metabolic syndrome and
obesity : targets and therapy 7: 305-312.
Conclusions • Gastric emptying integrates with insulin
secretion and action to regulate postprandial carbohydrate metabolism
• Gastric emptying affects postprandial glucose directly only when other parameters do not change
• Bariatric surgery provides insights into the interaction between the gut and the pancreas
©2012 MFMER | slide-45
©2012 MFMER | slide-46
Acknowledgments
University of Padua • Francesca Piccinini • Francesco Micheletto • Chiara Dalla Man • Claudio Cobelli
Vella Laboratory • Matheni Sathanthan • Meera Shah • Paula Giesler • Jeannette Laugen • Gail DeFoster
Robert Rizza Michael Camilleri Alan Zinsmeister Michael Jensen Michael Sarr Jim Swain Todd Kellogg
CTSA Study Subjects
©2012 MFMER | slide-47
Case Presentation • 54 year old female presenting with painful 1st
meta-tarso phalangeal joint.
• H/O DM 2 • diagnosed 8 years ago
• No evidence for microvascular complications
• Pertinent PMH • Hypothyroidism • GERD
Medications • Levothyroxine 137mcg once daily
• Omeprazole 20mg bid
• Metformin 1000mg bid
• Glimepiride 1mg daily
• Simvastatin 20mg daily
• Indomethacin 50mg 1-2 tablets q8hr PRN
Physical Examination • Weight 115kg
• BMI 40.3 kg/M2
• HR 80 min, BP 130 / 76 mmHg
• No respiratory distress
• Cardiorespiratory exam is unremarkable
• Inflamed, swollen left 1st MTP joint. Exquisitely tender to touch
Laboratory evaluation • Fasting glucose 138 mg/dL
• HbA1c 8.0%
• Uric acid 6.5 mg/dL (2.3 – 6.0)
• Lipids • Total Chol 204 mg/dL • TG 310 mg/dL • HDL 38 mg/dL • Calc LDL 104 mg/dL
Question 1 • Is the patient a candidate for bariatric surgery?
a)Yes – she meets clinical criteria
b)Yes – she will likely experience diabetes remission
c)No – it is unlikely that her diabetes will benefit from surgery
d)No – any consideration for surgery should come after detailed psychological assessment and completion of a lifestyle intervention program
©2012 MFMER | slide-52
Question 2 • What factors DO NOT affect diabetes remission
after bariatric surgery?
a)Prior duration of diabetes
b)Baseline weight
c)Prior therapy with insulin
d)Type of surgery
e)Number of medications prior to surgery
©2012 MFMER | slide-53
Question 3 • Which of the following is INCORRECT?
a)Gastric banding has good long-term outcomes
b)Duodenal sleeve is associated with hepatic abscess
c)Differences between sleeve gastrectomy and RYGB become apparent over time
d)After RYGB close follow up to ensure compliance with vitamin replacement therapy is required
©2012 MFMER | slide-54